Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
van Lint JA, van Hunsel FPAM, Tas SW, Vonkeman HE, Hoentjen F, van Doorn MBA, Hebing RCF, Nurmohamed MT, van den Bemt BJF, van Puijenbroek EP, Jessurun NT. van Lint JA, et al. Ann Rheum Dis. 2022 Apr;81(4):597-599. doi: 10.1136/annrheumdis-2021-221840. Epub 2021 Dec 16. Ann Rheum Dis. 2022. PMID: 34916208 No abstract available.
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
van Lint JA, Jessurun NT, Hebing RCF, Hoentjen F, Tas SW, Vonkeman HE, van Doorn MBA, Sobels A, Spuls PI, van Puijenbroek EP, Nurmohamed MT, van den Bemt BJF. van Lint JA, et al. Among authors: van doorn mba, van puijenbroek ep, van den bemt bjf. Drug Saf. 2020 Sep;43(9):917-925. doi: 10.1007/s40264-020-00946-z. Drug Saf. 2020. PMID: 32451974
Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
van Lint JA, Jessurun NT, Tas SW, van den Bemt BJF, Nurmohamed MT, van Doorn MBA, Spuls PI, van Tubergen AM, Ten Klooster PM, van Puijenbroek EP, Hoentjen F, Vonkeman HE. van Lint JA, et al. Among authors: van doorn mba, van puijenbroek ep, van tubergen am, van den bemt bjf. J Rheumatol. 2021 Sep;48(9):1388-1394. doi: 10.3899/jrheum.201373. Epub 2021 May 15. J Rheumatol. 2021. PMID: 33993115
Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
Thomas PWA, Römkens TEH, West RL, Russel MGVM, Jansen JM, van Lint JA, Jessurun NT, Hoentjen F. Thomas PWA, et al. Among authors: van lint ja. United European Gastroenterol J. 2021 Oct;9(8):919-928. doi: 10.1002/ueg2.12107. Epub 2021 Jun 2. United European Gastroenterol J. 2021. PMID: 34077634 Free PMC article.
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
Roest LH, Kosse LJ, van Lint JA, Gosselt HR, Scholl JHG, van Puijenbroek E, Vonkeman HE, Tas SW, Nurmohamed MT, van den Bemt BJF, Jessurun NT. Roest LH, et al. Among authors: van lint ja. Expert Opin Drug Saf. 2023 Mar;22(3):203-211. doi: 10.1080/14740338.2022.2115479. Epub 2022 Aug 28. Expert Opin Drug Saf. 2023. PMID: 36036179 Free article.
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K, Jessurun NT, Nguyen TDM, Scholl J, Jansen JRG, van Lint JA, Kosse LJ, Ten Klooster PM, Vonkeman HE. Velthuis K, et al. Among authors: van lint ja. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):485-492. doi: 10.1080/14740338.2023.2172157. Epub 2023 Jan 27. Expert Opin Drug Saf. 2023. PMID: 36683590
19 results